. Author manuscript; available in PMC: 2012 Sep 25.

Published in final edited form as: J Rheumatol. 2010 May 1;37(6):1136–1142. doi: 10.3899/jrheum.090994

Table 3.

Comparison of glucose metabolism by HCQ and disease status, by mean value adjusted for age, disease duration, waist circumference, prednisone dose, CRP, menopausal status, and NSAID; plus (a) immuno-suppressants and SLEDAI for women with SLE, or (b) nonbiologic DMARD (excluding HCQ) and TNF inhibitors for women with RA.

Metabolism Factors	+ HCQ	−HCQ	p
Fasting glucose, mg/dl
Women with SLE	85.9	89.3	0.04
Women with RA	82.5	86.6	0.051
_logInsulin
Women with SLE	2.53	2.64	0.18
Women with RA	2.44	2.36	0.37
_logHOMA-B
Women with SLE	5.40	5.37	0.78
Women with RA	5.46	5.20	0.06
_logHOMA-IR
Women with SLE	0.97	1.12	0.09
Women with RA	0.84	0.81	0.70

HCQ: hydroxychloroquine; SLE: systemic lupus erythematosus; RA: rheumatoid arthritis; HOMA-B: homeostasis model assessment - ß cell; HOMA-IR: homeostasis model assessment-insulin; CRP: C-reactive protein: NSAID: nonsteroidal aniinflammatory drug; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; DMARD: disease-modifying antirheumatic drug; TNF: tumor necrosis factor.